Invention Grant
- Patent Title: Dihydropyridone p1 as factor XIa inhibitors
- Patent Title (中): 二氢吡啶酮p1作为因子XIa抑制剂
-
Application No.: US14419002Application Date: 2013-08-02
-
Publication No.: US09409908B2Publication Date: 2016-08-09
- Inventor: Wu Yang , James R. Corte , Paul J. Gilligan , Donald J. P. Pinto , William R. Ewing , Andrew K. Dilger , Yufeng Wang , Tianan Fang , Kumar B. Pabbisetty , Leon M. Smith, II
- Applicant: Bristol-Myers Squibb Company
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Hong Liu
- International Application: PCT/US2013/053416 WO 20130802
- International Announcement: WO2014/022767 WO 20140206
- Main IPC: C07D401/04
- IPC: C07D401/04 ; C07D471/08 ; C07D487/08 ; C07D487/18 ; C07D471/18 ; C07H17/02

Abstract:
The present invention provides compounds of Formula (X):(Formula (X), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Public/Granted literature
- US20150203492A1 DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS Public/Granted day:2015-07-23
Information query